tirzepatide head to head semaglutide Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs Tirzepatide tops semaglutide for patient

For tirzepatide, 503A (traditional) pharmacies had until February 18, 2025, and 503B (outsourcing) facilities had until March 19, 2025 to stop their GLP-1 production

Be honest about your history, your weight, and your goals

For diabetes management, some patients remain at 0.5 mg, while others increase to 1 mg or the maximum dose of 2 mg based on glycemic response and tolerability

Safe for All Skin Types : RF energy is gentle and effective for a variety of skin tones

Declining estrogen affects body composition and fat storage in measurable ways

conducted a randomized, double-blind trial, so neither participants nor researchers knew who was receiving the drug versus a placebo over 400 adults with both obesity (BMI 30) and knee osteoarthritis (radiographically confirmed and quite painful)